Introduction: Data regarding the pre-treatment intertumor heterogeneity of potential biomarkers in advanced-stage lung cancers is limited. A finding of such heterogeneity between primary and metastatic lesions would prove valuable to determine if a metastatic lesion can be a surrogate for the primary tumor, as more biomarkers will likely be used in the future to inform treatment decisions.
Introduction
The recent development of personalized molecular targeted therapies in lung cancer based on genetic aberrations of tumor cells has dramatically improved the efficacy of systemic therapies and prolonged patient survival. [1] [2] [3] These personalized therapies include EGFR tyrosine kinase inhibitors (TKIs) for lung cancers with EGFR-activating mutations, anaplastic lymphoma kinase TKIs for those with ALK receptor tyrosine kinase (ALK) translocations, and ROS1-TKIs for those with ROS1 translocations. 1 Such targetable mutations, which are often called "oncogenic driver mutations," usually distribute homogeneously throughout and between lesions in a single patient. [4] [5] [6] [7] However, in the clinic, individual lesions in a patient sometimes respond to therapy differently, suggesting the potential of tumor heterogeneity at genetic and/or transcriptional levels between lesions. These intertumor heterogeneities could eventually inform future diagnostic strategies such that a metastatic lesion could serve as a surrogate for the primary tumor.
The data for tumor heterogeneity is especially important in patients with advanced-stage disease before the initiation of front-line systemic therapy. However, the analysis of innate tumor heterogeneity in lung cancer is challenging for various reasons: (1) surgical tumor resection is very rare in lung cancer patients with multiple metastases; (2) multiple biopsies are not standard practice for a single lung cancer patient (no perceived clinical benefit on decision making); and (3) systemic treatments, such as chemotherapies and molecular targeted therapies, affect mutational status and/ or gene expression status of tumor cells, altering the level of tumor heterogeneity. [8] [9] [10] [11] To date, three independent studies have compared genetic aberrations between multiple regions in surgically resected early-stage primary lung adenocarcinomas (intratumor heterogeneity), between multiple regions in clinically resectable NSCLCs (intratumor heterogeneity), or between multiple intrathoracic lesions obtained from operable NSCLCs. [5] [6] [7] However, no data regarding the intertumor heterogeneity is available for patients with advanced-stage disease.
To understand innate intertumor heterogeneity and investigate tumor evolution between primary and multiple metastatic lesions, we performed comprehensive RNA-sequencing (RNA-seq) analysis on multiple lesions obtained at autopsy from advanced-stage lung cancer patients who did not receive systemic anticancer therapy for various reasons.
Materials and Methods

Patients and Samples
Our cohort consisted of five autopsied lung cancer patients (two adenocarcinoma patients, two squamous cell carcinoma patients, and one SCLC patient) who did not receive systemic cancer treatment for various reasons including ages and performance status. Tissue specimens were obtained in accordance with ethical guidelines after obtaining written informed consent from their legal guardians as per the requirements of the Higashi-Hiroshima Medical Center (Higashi-Hiroshima, Japan). Tumor and noncancerous tissue were obtained at autopsy and were stored at -80 C in RNAlater RNA stabilization reagent (Qiagen, Hilden, Germany). Total RNA was extracted using the RNeasy Mini Kit (Qiagen) and the quality of RNA was assessed by the RNA integrity number score.
RNA Seq and Bioinformatic Analysis
The University of Colorado Cancer Center Genomics Shared Resource made extracted RNA into a cDNA library, and samples were sequenced on the Illumina HiSeq 4000 sequencer (Illumina; San Diego, CA) for 1 Â 150 cycles. Sequencing data were obtained and converted to FASTQ files. We mapped the sequencing reads to the hg19 reference genome using the TopHat/Cufflinks workflow as previously described. [12] [13] [14] [15] Transcripts were quantified using fragments per kilobase per million mapped reads (FPKM), and FPKM from all samples were quartile normalized before data analysis.
We used the gene set enrichment analysis (GSEA; gsea-3.0.jar version) for this analysis. 16 We used the Molecular Signatures Database Collection 2 curated Kyoto Encyclopedia of Genes and Genomes (KEGG) gene sets (c2.cp.kegg.v6.1.symbols.gmt) as the gene sets. For each patient, we compared the individual lesions against the normal sample using genotype permutation (n ¼ 1000). We considered pathways that have a nominal p less than 0.05 as significant and selected them for further analyses.
For the gene fusion detection, we used TopHat-Fusion for detecting gene fusions in the RNA-seq data. 17 We only considered a gene fusion to be positive when there are more than 20 supporting reads detected in each sample. For detecting mutations in the RNA-seq data, we adopted the IMPACT (Integrating Molecular Profiles with Actionable Therapeutics) whole-exome sequencing pipeline that we previously developed. 18 Briefly, IMPACT takes sequence data as an input and outputs a variant call format file containing predicted deleterious mutations. The sequencing reads were mapped to the human hg19 reference exome using the Burrows-Wheeler Aligner. 19, 20 SAMTools and BCFtools (v1.1) were used to detect variants from the Binary Alignment Map file and create a variant call format file output. In the IMPACT pipeline, we used ANNOVAR (v2014-11-12) to annotate the variants. 21, 22 Synonymous and intronic variants were removed. Nonsynonymous variants were further analyzed by deleterious prediction tools such as SIFT and PolyPhen2. 23, 24 To call a variant in RNA-seq, in this study, we used the following criteria and only called highconfidence somatic variants if the mutations were detected as somatic (after comparing with the paired normal sample), nonsynonymous, and deleterious mutations with total read counts 20 or more and variant read counts 5 or greater and 2% or greater.
To understand the development of tumor evolution, we identified acquired somatic and deleterious mutations on reliably expressed genes in different legions. We assumed that mutations occurred independently by chance. After generating the binary mutation matrices for each patient, we constructed phylogenetic trees for the multiple lesions of each patient using the Neighbor joining method implemented in the R phangorn package. 25 
Immunohistochemistry Analysis
Formalin-fixed, paraffin-embedded tumor tissues were sectioned, and then immunohistochemistry staining was performed using a programmed death ligand 1 (PD-L1) antibody (E1L3N, Cell Signaling Technology, Danvers, Massachusetts) as described previously. 26 A trained pathologist (S.S.) examined the proportions of the PD-L1-positive tumor cells.
Results
Samples and General RNA-Seq Data
Thirty lesions from five autopsied patients (range: 4 to 9 lesions per patient), as well as noncancerous tissue from each patient, were analyzed in this study (Table 1) . Histologically, this cohort consists of four NSCLC patients (two adenocarcinomas and two squamous cell carcinomas) and one SCLC patient. One adenocarcinoma patient was a never-smoker, whereas one of the squamous cell carcinoma patients and an SCLC patient were heavy smokers (50 or more pack-years). Total RNA was extracted from the lesions, and libraries of RNAs were constructed for RNA-seq profiling by next-generation sequencing (NGS). On average, we obtained approximately 61 million (range: 45 to 97 million) single-end 150 bp sequencing reads per sample, and the average mapping of 83.2% (53.9% to 90.4%) to the hg19 reference genome using the TopHat/Cufflinks workflow was performed as previously described (see Methods for details).
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Individual Tumors Have Unique Gene Expression Signatures
Initially we compared global gene expression data throughout lesions to determine which of the specific tumor characteristics or the microenvironment/metastasis site had a greater impact on gene expression status. As shown in Figure 1 , a global unsupervised clustering analysis of the expression data revealed that lesions from each patient clustered together, indicating that the global gene expression signature is affected more by the tumor cells themselves than the tumor microenvironment (i.e., specific metastatic sites). This suggests that if the global gene expression pattern is used as a biomarker, a metastatic lesion can be a surrogate for the primary lesion. We also observed that lesions from four NSCLC patients clustered together in contrast to lesions from the single SCLC patient. In addition, among NSCLC lesions, the two adenocarcinoma patients clustered together as did the two squamous cell carcinoma patients.
Intertumor Heterogeneity Based on Dysregulated Pathways
Next, we performed GSEA comparing lesions within a single patient to identify dysregulated pathways and compared dysregulated pathways between lesions (intertumor heterogeneity). 16 A heatmap of KEGG pathways with nominal p < 0.05 revealed 27 to 98 dysregulated pathways in each patient ( Figs. 2A and B, 3A Tables 2 and 3 , respectively), and in heavy smokers, only one (case 3) and five (case 5) dysregulated pathway(s) were shared in all lesions. Clustering analysis of these dysregulated pathways found that the primary lesions were always distinct from their respective metastatic lesions (Figs. 2B, 3B , and Supplementary Figs. 1B, 2B, and 3B ). In addition, we observed that data from metastatic lesions often clustered based on their metastatic sites (i.e., lymph node metastases, pleural or pulmonary metastases, and distant extrathoracic metastases). For example, in case 3, four distant metastases to abdominal organs (colon, retroperitoneum, and peritoneum) clustered together, a pulmonary metastasis and two pleural metastases (visceral and parietal) clustered together, and a hilar lymph node metastasis was distinct from other metastases (Fig. 3B) . We also found that pleural disseminations and pulmonary metastases often clustered together.
Dysregulated Pathways in Metastatic Lesions in NSCLC Lesions
Next, we investigated dysregulated pathways in metastatic lesions (compared to primary lesions) in NSCLCs to identify pathways that are upregulated or downregulated based on a metastatic pattern. Metastatic lesions were grouped into pleural disseminations, pulmonary metastases, distant metastases, and lymph node metastases. As shown in Supplementary Figure 4 , pathways related to cell proliferation (such as cell cycle, DNA replication and repair, RNA polymerase, and spliceosome) were upregulated in all metastatic patterns. On the other hand, immune-related pathways (such as allograft rejection, antigen processing and presentation, or natural killer cell mediated cytotoxicity) were downregulated in metastatic lesions compared to the primary lesions. In particular, we observed that multiple immune-related pathways were downregulated in pleural disseminations (Supplementary Fig. 5 ). These results suggest that the metastatic sites have diverse sets of dysregulated pathways compared with the primary lesions for promoting the metastatic potential and adapting to the foreign microenvironment.
Mutation Analyses in NSCLC Lesions
We also compared mutated genes between lesions in each patient. Because of the limitation of RNA-seq, we could only detect mutations in highly expressed genes (as defined below). Here we used the following criteria to extract high-confidence somatic variants: somatic/ nonsynonymous/and deleterious mutations with total read counts 20 or more and variant read counts 5 or more and 2% or more. We identified 272 to 442 mutations per each NSCLC patient.
We divided these mutations into three groups: trunk mutations (those present in all lesions), metastatic trunk mutations (those present in all metastases but not in primary lesions), and branch/private mutations. We observed that the numbers of trunk/metastatic trunk mutations were smallest in the squamous cell carcinoma patient with heavy-smoking status, followed by the two smokers (one with adenocarcinoma and one with squamous cell carcinoma), and the nonsmoking adenocarcinoma patient harbored the highest number of trunk/ metastatic trunk mutations (Table 2) . We next focused on the mutational analysis by evaluating a list of gene mutations that have been previously reported in NSCLCs by NGS. 5, 6, [27] [28] [29] [30] [31] [32] We also performed fusion gene detection using TopHat-Fusion on the RNA-seq results. We found that case 1 (a never-smoking adenocarcinoma patient) harbored a kinesin family member 5B (KIF5B)-ret protooncogene (RET) fusion as a trunk mutation (Fig. 2C) , Table 1 , and are excluded from the figure.) (C) Representative mutations identified in case 1. KIF5B-RET fusion was also identified in all lesions, but not in noncancerous tissue, using TopHat-Fusion on the RNA-seq. Insulin-like growth factor 2 receptor (IGF2R), major histocompatibility complex, class I, A (HLA-A), and erb-b2 receptor tyrosine kinase 2 (ERBB2) mutations were also identified as trunk mutations, whereas NF1 mutation was present only in some metastatic lesions. The phylogenetic tree was constructed using a Neighbor joining method implemented in the R phangom package, based on somatic and deleterious mutations in reliably expressed genes. The genes with asterisk indicate that somatic/deleterious mutations in those genes were identified in lesions obtained from the other lung adenocarcinoma patient (case 2). Representative mutations identified in case 3. Nuclear factor, erythroid 2 like 2 (NFE2L2) and integrin subunit beta 4 (ITGB4) mutations were identified in all lesions except for the hilar lymph node metastasis. The phylogenetic tree was constructed using a Neighbor joining method implemented in the R phangom package, based on somatic and deleterious mutations in reliably expressed genes. The genes with asterisks indicate that somatic/deleterious mutations in those genes were identified in lesions obtained from the other lung squamous cell carcinoma patient (case 4).
whereas the other adenocarcinoma patient had trunk RPTOR independent companion of MTOR complex 2 (RICTOR) and dual specificity phosphatase 5 (DUSP5) mutations, both of which may have the potential to be driver mutations (Supplementary Fig. 1C ). On the other hand, both of the squamous cell carcinoma patients harbored a trunk nuclear factor, erythroid 2 like 2 (NFE2L2) mutation, which was reported as one of the hallmark mutations in squamous cell carcinomas related to oxidative stress response. 28 We also detected a trunk integrin subunit beta 4 (ITGB4) mutation in both of the squamous cell carcinoma patients. Based on all of the detected mutations, we evaluated the evolution of lesions in each patient using a phylogenetic tree analysis. The results were similar to those obtained from the analysis of dysregulated pathways in cases 2 and 4, but were different from those in cases 1 and 3. However, similar to the results of the pathway analysis, the mutational status of primary lesions was distinct from that of metastatic lesions in all NSCLC cases. Our cohort had only one patient with SCLC who had a heavy-smoking history (case 5). We observed that only five dysregulated pathways were shared in all lesions analyzed ( Supplementary Fig. 3B) ; however, we found 63 trunk and 69 metastatic trunk mutations in this patient (Table 2) . A tumor pathway 53 (TP53) mutation, as well as a poly(ADPribose) polymerase 2 (PARP2) mutation, was identified as trunk mutation (Supplementary Fig. 3C ), whereas an abnormal spindle microtubule assembly (ASPM) mutation, which was reported by The Cancer Genome Atlas analysis, was identified in only one lymph node metastatic lesion. 28 The result of a phylogenetic tree analysis was the same as pathway analysis, revealing that the primary lesion was distinct from the metastatic lesions.
Intertumor Heterogeneity in Immune-Related Markers
Finally, we evaluated intertumor heterogeneity of immune markers that may predict the efficacy of current immunotherapy in lung cancers that target the programmed death 1/PD-L1 pathway. As shown in Figure 4 , the expression level of PD-L1 (CD274) and total numbers of somatic nonsynonymous mutations (not restricted to deleterious) varied significantly between lesions in each patient, suggesting an uncertainty of these markers as predictive biomarkers for immunotherapies. In addition, we did not observe any correlation between the PD-L1 expression and the numbers of mutations. PD-L1 protein expression was evaluated in lesions obtained from case 1. Sixty-percent of tumor cells were positive for PD-L1 in the primary lesion, whereas all metastatic lesions were negative (<1%) for PD-L1 staining. These results were compatible to the results of RNA expression data (Fig. 4) .
Discussion
Completion of The Cancer Genome Atlas project and other efforts using the NGS technique have provided enormous information about genetic aberrations in cancers, including lung cancers. [27] [28] [29] [30] [31] [32] [33] These studies have revealed the complexity of genomic alterations in lung cancers, and in addition, have identified potentially targetable genetic aberrations. However, these studies were not able to evaluate tumor heterogeneity, which would be clinically important when we try to target these genetic aberrations using molecular targeted agents or when we consider tumor tissue biopsy specimens from metastatic lesions as surrogates for primary tumors. Recent development of liquid biopsy enables us to detect mutations from different sites; however, the result of a liquid biopsy is affected by various factors (e.g., if tumors shed mutant DNA or not) and it is not possible to evaluate if the identified mutation is shared between lesions or not. 34 In this study, via a clustering analysis using gene expression data, we found that lesions obtained from each patient clustered together irrespective of the lesion location. This may indicate that when we use the gene expression signature as a biomarker, for example, as a predictive biomarker for immunotherapies, metastatic lesions can be a surrogate for primary tumors. 35 However, at the same time, we observed intertumor heterogeneity between a primary tumor and the metastatic lesions in terms of dysregulated pathways and somatic mutations. Our results suggest that the levels of tumor heterogeneity determined by either dysregulated pathways or somatic mutations were correlated with smoking status in NSCLCs; that is, higher levels of intertumor heterogeneity were observed in the heavy smoker, followed by smokers, and finally, by a nonsmoker. Although further studies are necessary to confirm these findings, we consider that our results are reasonable because cigarette smoking is related to higher mutation burden and genomic instability in cancers. 29, 36 Through the comparison of dysregulated pathways in our cohort, we identified that the primary lesions were always distinct from their metastatic counterparts. These data cannot be obtained from previous publications, including a large prospective TRACERx study that analyzed intratumor heterogeneity via multiregion sequencing within the primary lesions. 7 Our results indicate that a caution is necessary when we use a metastatic lesion as a surrogate for the primary tumor for some types of biomarker analysis (e.g., pathwaybased biomarkers or a somatic mutation with no evidence to be a trunk mutation).
We identified a KIF5B-RET fusion as a trunk mutation in all metastatic and primary lesions in an adenocarcinoma patient with nonsmoking history. Although the KIF5B-RET fusion is considered to drive lung cancers , recent clinical trials found that RET-TKIs for lung cancer patients with identified RET fusions were not as effective as EGFR-TKIs for those with EGFR mutations. 1, [37] [38] [39] [40] [41] [42] The results from this study may indicate that this lower efficacy is due to reasons other than the intertumor heterogeneity of RET fusion because our result showed a homogeneous distribution of this fusion gene. Currently, unlike the EGFR mutation or ALK receptor tyrosine kinase (ALK)/ROS1 fusion, RET fusion analysis is not routinely performed. Therefore, she did not have an opportunity to be treated with a specific TKI. For the other adenocarcinoma patient, we identified the RICTOR mutation as one of the trunk mutations. 43 In the analysis of squamous cell carcinoma patients, we identified the NFE2L2 mutation as a trunk mutation in both cases, suggesting its importance in squamous cell carcinomas. Both patients also harbored a trunk ITGB4 mutation; however, the collaborative role of these two mutated genes in squamous cell carcinomas is currently unclear. Nevertheless, our results indicate that these trunk mutations occurred at the early phase of tumorigenesis and may serve as driver mutations in lung cancers, Our comparison of metastatic lesions versus primary tumors in NSCLCs identified that pathways related to cell proliferation are upregulated whereas immune-related pathways are downregulated in metastatic sites. Among these metastatic patterns, pleural dissemination was the most immunosuppressive metastatic pattern. These differences may have a direct impact on the efficacy of treatment, especially for immunotherapeutic agents.
In summary, these data show both similarity and the heterogeneity between primary and metastatic lesions in lung cancer patients. Our results support the use of metastatic lesions as surrogates for primary lesions when we analyze the gene expression signature or trunk mutations, although we have to be aware that metastatic lesions are usually distinct from the primary tumors in terms of dysregulated pathways and mutational patterns.
